New cancer vaccine in development
A new vaccine is being heralded as a 'game changer’ [...]
Adjuvant pembrolizumab prolongs overall survival for kidney cancer patients
Surgery (partial or radical nephrectomy) is the standard of care [...]
Lenvatinib plus pembrolizumab for advanced kidney cancer
The final survival information from the phase 3 CLEAR study [...]
Patient’s perspective on pembrolizumab/lenvatinib for kidney cancer
In 2009, Cesar Fuentes was first diagnosed with kidney cancer [...]
Pembrolizumab plus lenvatinib for non-clear cell kidney cancer
Immunotherapy combinations are becoming the standard treatment for people with [...]
Pembrolizumab plus lenvatinib as first-line treatment for advanced non-clear cell kidney cancer
Immunotherapy combinations are becoming the standard treatment after surgery for [...]
Adjuvant therapy for kidney cancer
Adjuvant therapy aims to reduce the risk of the cancer [...]
Four-year follow-up with lenvatinib plus pembrolizumab for advanced kidney cancer
Further follow-up data from the phase 3 CLEAR study with [...]
Benefits persist for lenvatinib plus pembrolizumab in advanced kidney cancer
Lenvatinib plus pembrolizumab has already been shown to improve survival [...]
ASCO GU 2023: Adjuvant pembrolizumab for different risks and stages of kidney cancer
At the American Society of Clinical Oncology Genitourinary Cancers Symposium [...]
